Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.
BMJ open · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
AdolescentChildFemaleHumansMaleAntipsychotic AgentsBody Mass IndexDenmarkFeasibility StudiesGlucagon-Like Peptide-1 Receptor AgonistsMental DisordersPediatric ObesitySemaglutideObservational Studies as TopicChild & adolescent psychiatryClinical ProtocolsClinical Trial
Come citare questo studio
Laura Victoria Giraldi, Jon Trærup Andersen, Jonas Jespersen, Christoffer Storm Baden, Cilius Esmann Fonvig, Troels Riis, Kim Peder Dalhoff, Jens-Christian Holm, Anders Fink-Jensen, Anne Katrine Pagsberg, Mikkel Bring Christensen, Christina Gade. (2026). Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.. BMJ open. DOI: 10.1136/bmjopen-2026-123779
Consulta la pubblicazione originale ↗